Evidence Hub

Advances and perspectives in animal models of human hepatitis A virus

Jian Li, Pei Jiang, Hui Zhao, Cheng-Feng Qin

Animal Models and Experimental Medicine, 2026

Abstract

Abstract Hepatitis A virus (HAV) is an important pathogen that has continuously posed a threat to global public health for over 5000 years. The development of accessible and reliable small animal models, especially murine models, is essential for elucidating HAV pathogenesis and advancing preventive and therapeutic strategies. The first mouse model for HAV infection was established using human‐liver chimeric mice, which supported robust viral replication and high viral loads. Later, an Ifnar1 −/− mice model was established with a specific mouse‐adapted strain, recapitulating key clinical features of human hepatitis A. Recently, to overcome limitations associated with the difficulty in obtaining and amplifying stocks of HAV for animal models, our laboratory established a novel hepatitis A mouse model using lipid nanoparticle‐encapsulated viral genomic RNA (LNP‐vRNA). This approach provides a new strategy for modeling infections of hard‐to‐culture RNA viruses. In this review, we systematically summarize and compare these mouse models, respectively highlighting their advantages and limitations, and offer guidance for their application in future HAV research.

How strong is the evidence?

Evidence Hub reads this as a review, done in animal, not in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.

How the five levels of evidence work. The level is assigned automatically from the abstract and can be wrong, so check the paper.

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free